Events

Company awarded for excellence in innovation for Parteck® MXP Excipient and modified amino acids

OBN (UK) Ltd is delighted to announce the winners of the 2018 OBN Awards.

Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data

How does big pharma expand pipeline opportunities? What are the latest developments in partnering trends with Chinese investors? What innovations are most promising in rare disease and orphan drug development? These and many more industry-relevant questions will be addressed at the 24th annual BIO-Europe®, a global life science partnering event starting on November 5.

Come and join us at the 12th Algae Biomass Organization (ABO) Summit in Texas between October 14th to 17th at Booth #416.

Cardiovascular Research Foundation presents Aria with the Jon DeHaan Foundation

Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.

Eisai Co., Ltd. announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima/Kisplyx (lenvatinib mesylate, “lenvatinib”, selective inhibitor of receptor tyrosine kinases with a novel binding mode) and Halaven (eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor) will be presented during the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany, from October 19 to 23, 2018.

ObsEva SA today announced that IMPLANT 2 Phase 3 clinical data of its novel, oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF were presented at the 74th annual meeting ofthe American Society of Reproductive Medicine (ASRM), taking place in Denver, Colorado, October 6-10, 2018.

Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.